Cytel Sweden
We help life science companies succeed
Extensive Regulatory and Scientific Expertise
Cytel Sweden is a multi-disciplinary team of handpicked specialists with regulatory and scientific knowledge in medicinal product development and statistics. We aim to guide our clients in transforming their research hypotheses into full clinical studies.
Our Solutions
Clinical Trial Design and Adaptive Trial Design
At Cytel, we meticulously craft trial designs infused with advanced analytics, ensuring precision and regulatory compliance. Our approach enhances efficiency, elevating success probabilities while optimizing resources for seamless drug development journeys.
Toxicology Services for Safety and Risk Assessment
Toxicology, toxicokinetics, and safety pharmacology involve evaluating the possible adverse effects of a potential drug candidate and the systemic exposure at which such effects occur. Cytel can advise on planning, preparing, monitoring, and reviewing toxicology and safety pharmacology studies.
Regulatory Strategy
Many drug development projects fail due to time and funding constraints. Defining the regulatory strategy early during development increases the chances of doing the right thing at the right time.
Clinical Development Strategy and Planning
A successful clinical strategy involves a systematic and forward-looking framework encompassing several key components: clinical hypothesis, clinical endpoints and measures (PK/PD, biomarker, PRO), trial design, go/no-go milestone decision, patient population and more.
Clinical Pharmacology
Clinical pharmacology is a vital part of drug development. A solid clinical pharmacology program will ensure optimal doses are chosen for later-phase development and that labeling is sufficient for clinicians to prescribe the drug safely.
Medical Writing
High-quality medical writing is essential for regulatory compliance and conveying scientific research to diverse audiences. Lack of clarity in medical writing can result in misinterpretation of data/information, potentially impacting development decisions.
Nonclinical Development Design
Nonclinical development is a must in every drug development project as it determines a drug candidate's safety and efficacy before entering human trials in all phases of development.
Pharmaceutical Development & CMC
Pharmaceutical development and CMC aim to ensure that the medicinal drug is delivered to the right place, at the right time, and in the right amount every time it is administered to a patient.
Looking for the Team at SDS Life Science?
SDS Life Science is now known as Cytel. We take pride in the teams and relationships we’ve built over the years, and we’re committed to ensuring your drug development project moves seamlessly from the preclinical phase to market approval. The faces you’ve come to trust and the offices you’re familiar with remain unchanged.
Our locations
- Stockholm |Hagaplan 4, Forskaren, c/o The Park, plan 2
- Uppsala | Kungsängsgatan 35
Our Leadership
Maria is a Chemical Engineer with a long career in the drug development and CDMO space. With experience from several CEO and VP positions, Maria leads the Cytel Sweden expertise locally, with global synergies, providing the best way forward for sponsors.
Maria Lundberg
Managing Director, Cytel Sweden
Ulrika Andersson is a pharmacist with 25 years of experience in the pharmaceutical industry, in large pharma and global CDMOs. She has expertise in formulation science, focusing on clinical phase development and manufacturing, project leadership, pharmaceutical development, and commercial management.
Ulrika Andersson
Director of Drug Development
Maria has more than 20 years of experience in the life sciences industry, which, according to ICH-GCP, gives her a broad understanding of the drug development process from clinical trial planning and execution in phase I to phase IV.
Maria Fernström
Director of Clinical Project Management & Medical Writing
Anna Torrång is an experienced senior statistical consultant in drug development and medical research. Her area of expertise is statistical methods and analysis of clinical trials, from early to late phase, and she has experience in epidemiology research and observational studies.
Anna Torrång
Director of Biostatistics
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.
